[go: up one dir, main page]

KR920019930A - Probiotic - Google Patents

Probiotic Download PDF

Info

Publication number
KR920019930A
KR920019930A KR1019920005793A KR920005793A KR920019930A KR 920019930 A KR920019930 A KR 920019930A KR 1019920005793 A KR1019920005793 A KR 1019920005793A KR 920005793 A KR920005793 A KR 920005793A KR 920019930 A KR920019930 A KR 920019930A
Authority
KR
South Korea
Prior art keywords
enterococcus
composition
ibs
bacteria
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920005793A
Other languages
Korean (ko)
Other versions
KR0123456B1 (en
Inventor
데니스 알렌 윌리암
아넬리 링고드 마가렛
포터 필립
Original Assignee
원본 미기재
유니레버 엔 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본 미기재, 유니레버 엔 브이 filed Critical 원본 미기재
Publication of KR920019930A publication Critical patent/KR920019930A/en
Application granted granted Critical
Publication of KR0123456B1 publication Critical patent/KR0123456B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/21—Streptococcus, lactococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Dairy Products (AREA)
  • Seasonings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A novel strain of Enterococcus faecium, deposited as NCIMB 40371, has valuable probiotic properties and is particularly effective in alleviating symptoms of irritable bowel syndrome in human patients. The novel strain can be used in the manufacture of human foodstuffs.

Description

프로바이오틱 균Probiotic

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (30)

IBS를 겪고 있는 것으로 진단된 환자에게 1011개의 생존가능 세균을 단일의 경구 투영량으로서 투여하는 경우, 치료 후 5일 이상 동안 상기 환자로부터의 습윤변 g당 엔테로코커스(Entercoccus)균 105이상의 배설율을유지하며 치료 후 28일 이내에, 바람직하게는 14일 이내에 상기 환자의 IBS 증상 하나 이상을 완화시키는 에테로코커스 균.When 10 11 viable bacteria are administered as a single oral dose to a patient diagnosed with IBS, more than 10 5 excipient Entercoccus bacteria per gram of wet stool from the patient for at least 5 days after treatment. Eterococcus bacteria that maintain rates and relieve one or more symptoms of IBS within 28 days after treatment, preferably within 14 days. 제 1항에 있어서, 치료 후 10일 이내에 IBS 증상 하나 이상을 완화시키는 엔테로코커스 균.The Enterococcus bacterium according to claim 1, which alleviates one or more symptoms of IBS within 10 days after treatment. 제 1항에 있어서, 치료 후 7일 이내에 IBS 증상 하나 이상을 완화시키는 엔테로코커스 균.The Enterococcus bacterium according to claim 1, which alleviates one or more symptoms of IBS within 7 days after treatment. 제 1항-제 3항 중 어느 한 항에 있어서, 치료 후 10일 동안 환자로부터의 습윤변 g당 엔테로코커스 균 105의변 배설율을 유지하는 엔테로코커스 균.The Enterococcus bacterium according to any one of claims 1 to 3, which maintains a fecal excretion rate of Enterococcus bacteria 10 5 per gram of wet stool from the patient for 10 days after treatment. IBS를 겪고 있는 것으로 진단된 환자에게 1010개의 생존가능 세균을 매일의 단일 경구 투영량으로서 14일에 걸쳐 계속해서 투여하는 경우, 치료기간 동안 상기 환자로부터의 습윤변 g당 엔테로코커스 균 105이상의 변 배설율을 유지하며 상기 치료기간 중에 환자의 IBS 증상 하나 이상을 완화시키는 엔테로코커스 균.If 10 10 viable bacteria are continuously administered to a patient diagnosed with IBS over a 14-day period as a single oral daily dose, enterococcus bacteria per gram of wet stool from the patient during the treatment period will be at least 10 5. Enterococcus bacteria that maintain fecal excretion rate and relieve one or more symptoms of IBS during the treatment period. IBS를 겪고 있는 것으로 진단된 환자에게 1010개의 생존가능 세균을 매일의 단일 경구 투영량으로서 14일에 걸쳐 계속해서 투여하는 경우, 상기 치료기간 동안 상기 환자로부터의 습윤변 g당 엔테로코커스 균 105이상의 변 배설율을 유지하며 상기 치료기간 중에 환자의 IBS 증상 하나 이상을 완화시키는 엔테로코커스 균.When continuously administered over a 10 to 10 viable bacteria to patients diagnosed as suffering from IBS on the 14th day as a single oral projection amount of each day, Enterococcus bacteria per wet side from the patient g during the period of treatment 10 5 Enterococcus bacteria that maintain abnormal fecal excretion rates and relieve one or more symptoms of IBS during the treatment period. 제 1항-제 6항 중 어느 한 항에 따르는 엔테로코커스 파에큠(Enterococcus faecium) 균.Enterococcus faecium bacteria according to any one of claims 1 to 6. 균주 NCIMB 40371 및 이의 IBS-완화 돌연변이체 및 유도체로 이루어진 군중에서 선택되는 엔테로코커스파에큠 균.Enterococcus fae fungi selected from the group consisting of strain NCIMB 40371 and its IBS-releasing mutants and derivatives. 제 1항-제 8항 중 어느 한 항에 있어서, 생존가능 형태로 존재하는 균.The bacterium according to claim 1, which is in viable form. 제 1항-제 8항 중 어느 한 항에 있어서, 동결 건조된 형태로 존재하는 균.The bacterium according to any one of claims 1 to 8, which is present in lyophilized form. 담체물질 중에 제 1항-제 8항 중 어느 한 항에 따르는 생존가능 세균을 함유하는 식용 조성물.An edible composition containing the viable bacteria according to any one of claims 1 to 8 in a carrier material. 제 11항에 있어서, 발효 유제품인 식용 조성물.12. The edible composition of claim 11 which is a fermented dairy product. 제 11항에 있어서, 스프레드 또는 드레싱인 식용 조성물.The edible composition of claim 11 which is a spread or dressing. 제 11항에 있어서, 음료수인 식용 조성물.The edible composition of claim 11, which is a beverage. 제 1항-제 8항 중 어느 한 항에 따르는 생존가능 세균을 함유하는 식용 캡슐.An edible capsule containing the viable bacterium according to any one of claims 1 to 8. 제 1항-제 8항 중 어느 한 항에 따른 생존가능 세균을 조성물 g당 약 103개 이상의 생존가능 세균을 제공하기에 충분한 양으로 식용물질에 가하는 단계를 포함하는 프로바이오틱 조성물의 제조방법.A method of making a probiotic composition comprising adding a viable bacterium according to any one of claims 1 to 8 to an edible substance in an amount sufficient to provide at least about 10 3 viable bacteria per gram of the composition. . 위장질환 증세를 보이는 환자에게 대한 투여방식을 권고하는 지지사항을 기록하여 포장된, 담체물질 중에 엔테로코커스 파에큠 군주 NCIMB 40371의 생존가능 세균을 함유하는 식용 조성물.An edible composition containing the viable bacteria of Enterococcus paquent monarch NCIMB 40371, packaged in a carrier material, with supporting recommendations for the mode of administration for patients with gastrointestinal disease. 제 17항에 있어서, 담체물질이 수성인 조성물.18. The composition of claim 17, wherein the carrier material is aqueous. 제 17항에 있어서, 담체물질이 발효 유제품인 조성물.18. The composition of claim 17, wherein the carrier material is fermented dairy product. 제 17항에 있어서, 삽관법으로 투여하기에 적합한 조성물.18. The composition of claim 17 suitable for administration by intubation. 제 17항에 있어서, MCIMB 40371 세균을 동결 건조된 형태로 함유하는 조성물.18. The composition of claim 17 containing MCIMB 40371 bacteria in lyophilized form. 제 17항-제 21항 중 어느 한 항에 있어서, 질환이 IBS인 조성물.22. The composition of any one of claims 17-21, wherein the disease is IBS. 제 17항-제 22항 중 어느 한 항에 있어서, g당 균주 NCIMB 40371의 생존가능세균 약 103개 이상을 함유하는 조성물.23. The composition of any one of claims 17-22, containing at least about 10 3 viable bacteria of strain NCIMB 40371 per gram. 제 17항-제 22항 중 어느 한 항에 있어서, g당 균주 NCIMB 40371의 생존가능세균 약 106개 이상을 함유하는 조성물.23. The composition of any one of claims 17-22 containing at least about 10 6 viable bacteria of strain NCIMB 40371 per gram. 제 17항-제 22항 중 어느 한 항에 있어서, g당 균주 NCIMB 40371의 생존가능세균 약 109-약 1010을 함유하는 조성물.23. The composition of any one of claims 17-22 containing about 10 9 -about 10 10 viable bacteria of strain NCIMB 40371 per gram. 위장질환, 특히 IBS 증상을 보이는 환자에게 투여하기 위한 조성물의 제조에 사용되는 엔테로코커스 파에큠 균주 NCIMB 40371의 용도.Use of Enterococcus faeche strain NCIMB 40371 used in the preparation of a composition for administration to a patient with gastrointestinal disorders, especially with IBS symptoms. 엔테로코커스 파에큠 균주 NCIMB 40371의 생존가능 세균을 함유하는 식용 조성물을 환자의 위장관에서 상기 균주의 개체군을 안정 및/또는 유지시키기에 충분한 양으로 경구투여 함으로써 환자의 위장질환 증세를 완화시키는 방법.A method of alleviating gastrointestinal symptoms of a patient by orally administering an edible composition containing viable bacteria of Enterococcus faeche strain NCIMB 40371 in an amount sufficient to stabilize and / or maintain a population of said strain in the gastrointestinal tract of the patient. 엔테로코커스 파에큠 균주 NCIMB 40371의 생존가능 세균을 함유하는 식용 조성물을 환자의 위장관에서 상기 균주의 개체군을 안정 및/또는 유지하기에 충분한 양으로 경구투여 함으로써 환자의 IBS 증상을 완화시키는 방법.A method of alleviating IBS symptoms in a patient by orally administering an edible composition containing the viable bacteria of Enterococcus faeche strain NCIMB 40371 in an amount sufficient to stabilize and / or maintain a population of said strain in the patient's gastrointestinal tract. 엔테로코커스 파에큠 균주 NCIMB 40371의 생존가능 세균을 함유하는 발효 유제품을 반복 투여함으로써 환자의 IBS 증상을 완화시키는 방법.A method of alleviating the symptoms of IBS in a patient by repeated administration of fermented dairy products containing viable bacteria of Enterococcus faeche strain NCIMB 40371. 제 11항-제 25항 중 어느 한 항에 따르는 조성물을 함유하는, IBS 증상을 보이는 환자를 위한 조절식품.Modified food for patients with IBS symptoms, comprising the composition according to any one of claims 11-25. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920005793A 1991-04-08 1992-04-08 Probiotic Expired - Fee Related KR0123456B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919107305A GB9107305D0 (en) 1991-04-08 1991-04-08 Probiotic
GB9107305.6 1991-04-08

Publications (2)

Publication Number Publication Date
KR920019930A true KR920019930A (en) 1992-11-20
KR0123456B1 KR0123456B1 (en) 1997-11-19

Family

ID=10692798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005793A Expired - Fee Related KR0123456B1 (en) 1991-04-08 1992-04-08 Probiotic

Country Status (14)

Country Link
US (2) US5589168A (en)
EP (1) EP0508701B1 (en)
JP (1) JP3186202B2 (en)
KR (1) KR0123456B1 (en)
AT (1) ATE140265T1 (en)
AU (1) AU652815B2 (en)
CA (1) CA2064954A1 (en)
DE (1) DE69212034T2 (en)
DK (1) DK0508701T3 (en)
ES (1) ES2089398T3 (en)
GB (1) GB9107305D0 (en)
GR (1) GR3021069T3 (en)
IE (1) IE921092A1 (en)
NZ (1) NZ242195A (en)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5630410A (en) * 1996-01-04 1997-05-20 Us Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
WO1997045530A1 (en) * 1996-05-27 1997-12-04 UZILOVA, Irina Semenovna, Heiress of UZILOV Use of streptococcus faecium strains and composition containing the same
US6583275B1 (en) 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US5965128A (en) * 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5879719A (en) * 1997-08-28 1999-03-09 Midwest Zoological Research, Inc. Process for control, elimination or inhibition of salmonellae in reptiles and/or amphibians
IT1298918B1 (en) * 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
US6283294B1 (en) * 1999-09-01 2001-09-04 Biogaia Biologics Ab Enclosed living cell dispensing tube
US20040047868A1 (en) * 2000-07-03 2004-03-11 Gerald Pang Treating endotoxemia and related disorders with probiotics
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
FR2814913B1 (en) * 2000-10-11 2005-06-03 Amora Maille EDIBLE EMULSION COMPRISING LIVE MICROORGANISMS AND VINAIGRETTE OR ACCOMPANYING SAUCE COMPRISING THE SAME EDIBLE EMULSION
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
NZ515881A (en) * 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
RU2220199C1 (en) * 2002-07-03 2003-12-27 Алехина Галина Геннадьевна Enterococcus strain enterococcus faecium l-3 for preparing curative-prophylactic agents and foodstuffs of curative-prophylactic designation
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20050042207A1 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation Stable liquid probiotic composition, preparation and applications thereof
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
RU2006114790A (en) * 2003-10-02 2007-11-20 Дзе Байо Бэлэнс Корпорейшн (Us) DRY BIOTHERAPEUTIC COMPOSITION, ITS APPLICATION, DEVICE AND METHODS FOR ITS INTRODUCTION
US20070009490A1 (en) * 2003-10-02 2007-01-11 Conte Anthony E Dried biotherapeutic composition, uses, and device and methods for administration thereof
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
NO20050044L (en) * 2005-01-04 2006-07-05 Innovest As Preparation for the treatment of Colitis ulcerosa & Chrohn's disease
BRPI0611493B1 (en) 2005-05-31 2022-04-05 Alimentary Health Ltd. Feline probiotic lactobacilli
PL1885383T3 (en) 2005-05-31 2017-06-30 Iams Europe B.V. Feline probiotic bifidobacteria
WO2007038466A2 (en) 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
CN101711158A (en) 2007-02-01 2010-05-19 爱默思公司 Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
WO2009140613A1 (en) * 2008-05-15 2009-11-19 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
MX2013010343A (en) 2011-03-09 2014-04-30 Univ Minnesota COMPOSITION AND METHODS FOR THE TRANSPLANT OF MICROBIOTA DE COLON.
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2925332A4 (en) 2012-08-20 2016-12-21 Boris Markosian PLACENTAL VACCINATION THERAPY AGAINST CANCER
CN103060224B (en) * 2012-09-26 2015-03-18 中国人民解放军总医院 Space enterococcus faecium LCT-EF258 strain
US20150374763A1 (en) 2013-02-05 2015-12-31 Ludwig Stocker Hofpfisterei Gmbh Use of microorganisms for the prevention and treatment of intestinal diseases
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR101737332B1 (en) 2014-11-24 2017-05-18 고려대학교 산학협력단 New Enterococcus faecium L11 and probiotics composition comprising the same
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
SG10202010444UA (en) 2014-12-05 2020-11-27 Synlogic Operating Co Inc Bacteria engineered to treat diseases associated with hyperammonemia
EP3227440B1 (en) 2014-12-05 2021-07-14 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
KR101702945B1 (en) 2014-12-17 2017-02-06 삼성중공업 주식회사 Distributed control system and control method thereof
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
ES2668934T3 (en) 2014-12-23 2018-05-23 4D Pharma Research Limited Pirin polypeptide and immune modulation
JP6271093B1 (en) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Immunoregulation
CA2978315A1 (en) 2015-03-02 2016-09-09 Synlogic, Inc. Bacteria engineered to produce butyrate under low oxygen or anaerobic conditions and uses thereof
ES2881384T3 (en) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Engineered bacteria to reduce hyperphenylalaninemia
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
AU2016262615C1 (en) 2015-05-14 2021-06-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
JP6856968B2 (en) 2015-05-22 2021-04-14 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ Methods for treating autism spectrum disorders and related symptoms
WO2016200614A2 (en) 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
EP4056191A1 (en) 2015-06-15 2022-09-14 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016278070B2 (en) 2015-06-15 2021-09-09 Cj Bioscience, Inc. Compositions comprising bacterial strains
PE20180243A1 (en) 2015-06-15 2018-01-31 4D Pharma Res Ltd COMPOSITIONS INCLUDING BACTERIAL STRAINS
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
WO2016210378A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Multi-layered control of gene expression in genetically engineered bacteria
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
JP2018521674A (en) 2015-07-31 2018-08-09 シンロジック オペレーティング カンパニー インコーポレイテッド Bacteria engineered to treat disorders with propionate catabolism
EP3344266A1 (en) 2015-08-31 2018-07-11 Synlogic, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
JP2018532412A (en) 2015-10-30 2018-11-08 シンロジック オペレーティング カンパニー インコーポレイテッド Bacteria engineered to treat diseases that benefit from reduced gastrointestinal inflammation and / or enhanced gastrointestinal mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017075485A1 (en) 2015-10-30 2017-05-04 Synlogic, Inc. Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
PL3377518T3 (en) 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
SG11201804161VA (en) 2015-11-20 2018-06-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017123610A2 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to detoxify deleterious molecules
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017123592A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat disorders associated with bile salts
WO2017123676A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
EP3402497A1 (en) 2016-01-11 2018-11-21 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
CA3013770A1 (en) 2016-02-04 2017-08-10 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
WO2017139697A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Composition comprising a bacterial strain
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
AU2018205276A1 (en) 2017-01-06 2019-07-18 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3582808B1 (en) 2017-02-15 2024-02-07 The Medical College of Wisconsin, Inc. Engineered bacterial strain that reduces antibiotic-resistant enterococcus colonization in the gi tract
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020513018A (en) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー Compositions and methods for treating Parkinson's disease (PD) and related disorders
KR20200019882A (en) 2017-05-22 2020-02-25 4디 파마 리서치 리미티드 Compositions Containing Bacterial Strains
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
BR112019026477A2 (en) 2017-06-14 2020-07-14 4D Pharma Research Limited compositions comprising bacterial strains
JP6837581B2 (en) 2017-06-14 2021-03-03 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Compositions Containing Bacterial Strains of the Genus Megasphaera and Their Use
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
US10941433B2 (en) 2017-06-15 2021-03-09 Iowa State University Research Foundation, Inc. Neurotransmitter transport in probiotics
US11879123B2 (en) 2017-06-21 2024-01-23 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
AU2018301668A1 (en) 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
JP2020529431A (en) * 2017-08-10 2020-10-08 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Composition Containing Bacterial Strain
US20210130806A1 (en) 2017-11-03 2021-05-06 Synlogic Operating Company, Inc. Engineered bacteria expressing racemase for treating diseases associated with hyperammonemia
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
JP2022530503A (en) 2019-04-29 2022-06-29 シンロジック オペレーティング カンパニー インコーポレイテッド Genetically engineered microorganisms
KR102149185B1 (en) * 2019-05-09 2020-08-28 한국 한의학 연구원 Enterococcus lactis Wikim0107 strain controlling immune function and ameliorating inflammatory bowel disease and use thereof
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
JP2022548785A (en) 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド Compositions and methods for treatment of inflammatory and immune disorders
BR112022012629A2 (en) 2019-12-24 2022-09-06 Univ Iowa State Res Found Inc HISTAMINE CONTROL TO PROMOTE HEALTH AND CONTROL ENTEROCOLITIS USING PROBIOTIC COMPOSITIONS AND/OR HISTAMINE DEGRADING ENZYMES
IL295353A (en) 2020-03-20 2022-10-01 Synlogic Operating Co Inc Microorganisms engineered to reduce hyperphenylalaninemia
BR112023002758A2 (en) 2020-08-14 2023-05-02 Prolacta Bioscience Inc COMPOSITIONS OF HUMAN MILK OLIGOSACCHARIDES FOR USE WITH BACTERIOTHERAPIES
US20240110191A1 (en) 2020-12-02 2024-04-04 Synlogic Operating Company, Inc. Engineered microorganisms
WO2022146718A1 (en) 2020-12-31 2022-07-07 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
EP4277634A1 (en) 2021-01-12 2023-11-22 Prolacta Bioscience, Inc. Synbiotic treatment regimens
US20240191176A1 (en) 2021-04-13 2024-06-13 Synlogic Operating Company, Inc. Bacteria engineered to secrete active proteins
RU2766765C1 (en) * 2021-05-25 2022-03-15 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Method for treatment of functional diseases of gastrointestinal tract in children
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
WO2023245171A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
WO2023245168A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
EP4543472A1 (en) 2022-06-22 2025-04-30 Iowa State University Research Foundation, Inc. Control of histamine to promote health and control enterocolitis using probiotic compositions
EP4543470A1 (en) 2022-06-23 2025-04-30 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
WO2024081768A1 (en) 2022-10-12 2024-04-18 Synlogic Operating Company, Inc. Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
WO2024086557A1 (en) 2022-10-17 2024-04-25 Synlogic Operating Company, Inc. Recombinant bacteria expressing phenylalanine ammonia lyase, phenylalanine transporter and l- aminoacid deaminase for reducing hyperphenylalaninemia
WO2024129974A1 (en) 2022-12-14 2024-06-20 Synlogic Operating Company, Inc. Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental
WO2024130119A2 (en) 2022-12-16 2024-06-20 Prolacta Bioscience, Inc. Synbiotic compositions for short chain fatty acid production

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1771677B2 (en) * 1968-06-25 1972-09-07 Hoesch Ag, 4600 Dortmund METHOD AND DEVICE FOR APPLYING AN ENAMEL-LIKE COATING LAYER, WHICH MAY CONTAIN AN CORROSION PROTECTION AGENT, AS AN CORROSION PROTECTION LAYER ON METALLIC ROLLED MATERIAL
JPS5927833A (en) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd Novel microorganism belonging to genus streptococcus
JPS615022A (en) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd Ameliorant of enterobacterial flora
DE3509239A1 (en) * 1985-03-14 1986-09-18 Angelo 8137 Berg Schuler Dietetic composition
SE8702435L (en) * 1987-06-11 1988-12-12 Medipharm Ab COULD INCREASE THE PROTEIN CONTENTS IN MILK WITH MILK PRODUCING ANIMALS
JPS6483025A (en) * 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
AU640349B2 (en) * 1988-08-02 1993-08-26 Borody, Thomas J Dr Treatment of gastro-intestinal disorders
US5116737A (en) * 1989-03-14 1992-05-26 Chr. Hansen's Laboratory, Inc. Method for growing acid-producing bacteria
US5292657A (en) * 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella

Also Published As

Publication number Publication date
JP3186202B2 (en) 2001-07-11
NZ242195A (en) 1995-04-27
EP0508701A2 (en) 1992-10-14
AU1473892A (en) 1992-10-15
DE69212034T2 (en) 1997-01-23
EP0508701A3 (en) 1993-05-05
AU652815B2 (en) 1994-09-08
GB9107305D0 (en) 1991-05-22
IE921092A1 (en) 1992-10-21
GR3021069T3 (en) 1996-12-31
US5728380A (en) 1998-03-17
ATE140265T1 (en) 1996-07-15
DK0508701T3 (en) 1996-10-28
US5589168A (en) 1996-12-31
KR0123456B1 (en) 1997-11-19
EP0508701B1 (en) 1996-07-10
DE69212034D1 (en) 1996-08-14
JPH05252934A (en) 1993-10-05
ES2089398T3 (en) 1996-10-01
CA2064954A1 (en) 1992-10-09

Similar Documents

Publication Publication Date Title
KR920019930A (en) Probiotic
Saran et al. Use of fermented foods to combat stunting and failure to thrive
JP5121715B2 (en) Moisturizer
KR101349452B1 (en) Novel lactobacillus strains and their use against helicobacter pylori
US20160220620A1 (en) Probiotic compositions for use in the treatment of bowel diseases
CN113355255B (en) Lactobacillus reuteri LM1071 strain and composition comprising the culture thereof
JP5232404B2 (en) Anti-cold virus or anti-influenza virus composition containing sporic lactic acid bacteria
BRPI0011799B1 (en) lactic acid bacterium composition and its use for the prevention and / or treatment of infections and inflammatory conditions
EP0923293A1 (en) Treatment of diarrhea
KR20110124780A (en) Prebiotic Formulations and Methods of Use
WO2013063849A1 (en) Application of roseburia in treating and preventing obesity related diseases
JPH07242557A (en) Laxative-containing laxative composition
JPH0138084B2 (en)
KR20100102178A (en) Method for decreasing abdominal girth by administering a bifidobacterium bacteria
JPH107577A (en) Hypoglycemic agent
AU773079B2 (en) Immunopotentiating compositions
JPH03151854A (en) Intestinal harmful putrefaction product reducing agent
JPS61171423A (en) Drug for alleviating dental caries and periodontosis
TW200404536A (en) New pharmaceutical composition
EP3721889B1 (en) Butyribacter intestini for use in preventing and/or treating inflammatory bowel disease
US3651214A (en) Orally administrable polyvalent vaccines for intestinal infections
JP7200298B2 (en) Suppressant for diarrhea-type irritable bowel syndrome and food composition
EP3806876B1 (en) Lactobacillus plantarum compositions and uses thereof
CN110448569B (en) Composition with antidiarrheal effect, preparation method and application thereof
JPH11158075A (en) Pancreatic function regulator

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20000913

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20000913

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301